AZD 3759

Drug Profile

AZD 3759

Alternative Names: AZD-3759; EGFR antagonist - AstraZeneca; Epidermal growth factor receptor tyrosine kinase inhibitor - AstraZeneca

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Amines; Antineoplastics; Piperazines; Quinazolines
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 30 Oct 2017 Phase-I/II clinical trials in Non-small cell lung cancer (Late-stage disease) in China (PO) (NCT03360929)
  • 02 Jun 2017 Interim efficacy, adverse events and pharmacokinetics data from the phase I BLOOM trial in Non-small cell lung Cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 29 Apr 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top